TVGN - NASDAQ
Tevogen Bio Holdings Inc.
$0.25
-5.8%Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
At a Glance
Live SnapshotTevogen Bio Holdings Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Working Capital
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Tevogen Bio Holdings Inc. Balance Sheet
TVGN • NASDAQ
| Tevogen Bio Holdings Inc. Balance Sheet | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
ASSETS | ||||
CURRENT ASSETS | ||||
1.3M | 1.1M | 5.5M | 7.1M | |
1.3M | 1.1M | 5.5M | 7.1M | |
158.8K | 0.0 | 0.0 | 0.0 | |
158.8K | 0.0 | 0.0 | 0.0 | |
0.0 | 670.6K | 353K | 0.0 | |
919.1K | 0.0 | 0.0 | 54K | |
2.4M | 1.7M | 5.8M | 7.2M | |
NON-CURRENT ASSETS | ||||
524.9K | 928.5K | 1.3M | 142.6K | |
0.0 | 0.0 | 0.0 | 351.9M | |
575.8K | 2.9M | 594.9K | -351.6M | |
1.1M | 3.8M | 1.9M | 485.3K | |
3.5M | 5.5M | 7.7M | 7.7M | |
LIABILITIES | ||||
CURRENT LIABILITIES | ||||
5.5M | 3.4M | 865.9K | 378K | |
5.2M | 3.4M | 865.9K | 378K | |
250K | 0.0 | 0.0 | 0.0 | |
1.3M | 976.3K | 578.8K | 244.7K | |
1.7M | 80.7M | 0.0 | 0.0 | |
229.1K | 252.7K | 278.2K | 0.0 | |
403.2K | 120.1K | 237.6K | 45.3K | |
9M | 85.5M | 2M | 667.9K | |
NON-CURRENT LIABILITIES | ||||
1M | 14.2M | 39.3M | 23.5M | |
87.2K | 0.0 | 0.0 | 0.0 | |
1.1M | 14.5M | 39.7M | 23.5M | |
234.9K | 487.6K | 710.9K | 0.0 | |
10.1M | 99.9M | 41.7M | 24.1M | |
SHAREHOLDERS' EQUITY | ||||
8.8M | 0.0 | 0.0 | 0.0 | |
17.8K | 12K | 61.9K | 63.9K | |
97.9M | 5.2M | 5.2M | 586.2K | |
-113.4M | -99.7M | -39.2M | -17.1M | |
-6.7M | -94.4M | -34M | -16.5M | |
-6.7M | -94.4M | -34M | -16.5M | |
SUMMARY | ||||
3.5M | 5.5M | 7.7M | 7.7M | |
0.0 | 0.0 | 0.0 | 351.9M | |
2.9M | 95.4M | 40M | 23.5M | |
1.6M | 94.4M | 34.5M | 16.4M | |
196,705,067 | 196,705,067 | 196,705,067 | 196,705,067 |
SEC Filings
TVGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | February 25, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 30, 2026 | January 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | January 26, 2026 | January 26, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 26, 2025 | September 23, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 14, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 10, 2025 | July 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 03, 2025 | July 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 30, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 23, 2025 | June 23, 2025 | 2025 |
Related Guides
Continue your TVGN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.